论文部分内容阅读
目的考察依达拉奉联合丹红注射液治疗治疗急性脑梗死的临床疗效及安全性。方法选择2012年11月-2015年3月医院收治的急性脑梗死患者80例,随机分为观察组与对照组各40例,对照组给予常规药物(丹红注射液、胞二磷胆碱、肠溶阿司匹林等)治疗,观察组加用依达拉奉,2周后进行疗效、神经功能缺损评分和不良反应评定。结果治疗后,观察组神经功能缺损评分(8.7±1.8)分,对照组神经功能缺损评分(13.2±2.2)分,差异有统计学意义(P<0.05);观察组总有效率为83.3%高于对照组总有效率为72.5%,2组疗效比较差异有统计学意义(P<0.05),2组均未见明显不良反应。结论依达拉奉联合丹红注射液治疗脑梗死疗效确切,能程度改善神经功能缺损情况,安全可靠。
Objective To investigate the clinical efficacy and safety of edaravone combined with Danhong injection in the treatment of acute cerebral infarction. Methods Eighty patients with acute cerebral infarction admitted from November 2012 to March 2015 in our hospital were randomly divided into observation group (40 cases) and control group (40 cases). The control group was given conventional drugs (Danhong injection, citicoline, Enteric-coated aspirin, etc.) treatment, the observation group plus edaravone, two weeks after the treatment, neurological deficit score and adverse reaction assessment. Results After treatment, the neurological deficit score (8.7 ± 1.8) in the observation group and the neurological deficit score (13.2 ± 2.2) in the control group were statistically significant (P <0.05). The total effective rate in the observation group was 83.3% The total effective rate in the control group was 72.5%. There was significant difference between the two groups (P <0.05). No obvious adverse reactions were found in the two groups. Conclusion Edaravone combined with Danhong injection for the treatment of cerebral infarction is effective and can improve neurological deficit to a certain degree, which is safe and reliable.